HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Huang, Dan ^a   Lu, Ning ^b   Fan, Qinhe ^c   Sheng, Weiqi ^a   Bu, Hong ^d   Jin, Xiaolong ^e   Li, Guimei ^f   Liu, Yanhui ^g   Li, Xianghong ^h   Sun, Wenyong ⁱ   Zhang, Huizhong ^j   Li, Xiaobing ^k   Zhou, Zongguang ^d   Yan, Min ^e   Wang, Xuan ^f   Sha, Weihong ^g   Ji, Jiafu ^h   Cheng, Xiangdong ⁱ   Zhou, Zhiwei ^j   Xu, Jianming ^k   Du, Xiang ^a   more..

^a FUDAN UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f PLA   (China)

^g GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^h PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

ⁱ ZHEJIANG CANCER HOSPITAL   (China)

^j SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^k Beijing 307 Hospital   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CHINA; CONTROLLED STUDY; DUAL COLOR SILVER ENHANCED IN SITU HYBRIDIZATION; EARLY CANCER; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REPRODUCIBILITY; STOMACH CANCER; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; STOMACH TUMOR;

ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893622386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080290     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Jing JJ, Liu HY, Hao JK, Wang LN, Wang YP et al. (2012) Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol 18: 1262-1269. doi:10.3748/wjg.v18.i11.1262. PubMed: 22468091.
3. Zhang J, Dhakal IB, Zhao Z, Li L (2012) Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev 21: 480-489. doi: 10.1097/CEJ. 0b013e328351c732. PubMed: 22357483.
4. Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20. PubMed: 16440411.
5. Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI (2011) Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev 20: 183-186. doi:10.1158/1055-9965.EPI-10-0802. PubMed: 21127287.
6. Yamashita K, Sakuramoto S, Nemoto M, Shibata T, Mieno H et al. (2011) Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol 17: 3390-3397. doi:10.3748/wjg.v17.i29.3390. PubMed: 21876631.
7. Lindblad M, Ye W, Lindgren A, Lagergren J (2006) Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg 243: 479-485. doi: 10.1097/01.sla.0000205825. 34452.43. PubMed: 16552198.
8. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697. doi:10.1016/S0140-6736(10)61121-X. PubMed: 20728210.
9. Zhang M, Li Z, Ma Y, Zhu G, Zhang H et al. (2012) Prognostic predictors of patients with carcinoma of the gastric cardia. Hepatogastroenterology 59: 930-933. PubMed: 22469742.
10. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A et al. (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299-307. doi:10.1007/s00428-010-0952-2. PubMed: 20665045.
11. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H et al. (2010) Her2 testing in gastric cancer. What is different in comparison to breast cancer?. Pathologe 31: 208-217. doi:10.1007/s00292-010-1278-1. PubMed: 20443098.
12. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M et al. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805. doi:10.1111/j.1365-2559.2008. 03028.x. PubMed: 18422971. (Pubitemid 351724903)
13. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM et al. (2013) HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 24: 2360-2364. doi:10.1093/annonc/mdt232. PubMed: 23788757.
14. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY et al. (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25: 637-650. doi:10.1038/modpathol.2011.198. PubMed: 22222640.
15. García-García E, Gómez-Martín C, Angulo B, Conde E, Suárez-Gauthier A et al. (2011) Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dualcolour silver in-situ hybridization method. Histopathology 59: 8-17. doi: 10.1111/j.1365-2559.2011.03894.x. PubMed: 21771023.
16. Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14: 101-112. doi:10.1007/s10120-011-0041-5. PubMed: 21573743.
17. Babic A, Loftin IR, Stanislaw S, Wang M, Miller R et al. (2010) The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods 52: 287-300. doi:10.1016/j.ymeth.2010.08.012. PubMed: 20807574.
18. American Joint Committee on Cancer (2010). he TNM staging classification.
19. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M et al. (2011) Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 17: 5060-5070. doi: 10.1158/1078-0432.CCR-10-2927. PubMed: 21700765.
20. Gomez L, Concha A, Garcia-Caballero T, Busteros JI (2012) Assessment of HER2 status from an epidemiology study in tumor tissue samples of gastric and gastro-esophageal junction cancer: Spanish results of the HER-EAGLE study. ASCO Annual Meeting J Clin Oncol abstr: 4089
21. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP et al. (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 23: 2656-2662. doi:10.1093/annonc/mds104. PubMed: 22689179.
22. Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM et al. (2012) Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43: 413-422. doi: 10.1016/j.humpath.2011.05.019. PubMed: 21855114.
23. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K et al. (2013) HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 16: 84-93. doi:10.1007/s10120-012-0150-9. PubMed: 22410801.
24. Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP, Macgrogan G, Vincent-Salomon A et al. (2006) High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur J Cancer 42: 2946-2953. doi:10.1016/j.ejca.2006. 06.020. PubMed: 16989997. (Pubitemid 44667473)